不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞淋巴瘤一线治疗的进展与个体化策略
英文原题：Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas.
查看英文原题
Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
外周T细胞淋巴瘤（PTCL）是一类罕见且异质性高的非霍奇金淋巴瘤，临床病程具有侵袭性。历史上，PTCL治疗方案仿照侵袭性B细胞淋巴瘤；但事实已明确，采用几乎相同的化疗策略时，PTCL总体缓解率和完全缓解率远低于B细胞淋巴瘤。近年来出现大量针对特定PTCL亚型独特细胞和分子特征的新药。在复发、难治及一线治疗阶段，这些药物已证明能产生更强抗淋巴瘤应答，部分情况下还能改善总生存期。本文总结并重点介绍推动多种PTCL新疗法获美国食品药品监督管理局（FDA）批准的关键临床试验，特别关注新兴研究及扩大其一线治疗应用范围的策略。
展开英文摘要原文
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous subset of non-Hodgkin lymphoma characterized by an aggressive clinical course. Historically, the treatment of PTCLs have been analogous to that of aggressive B-cell lymphomas; however, it has been well-established that overall responses and complete remission rates are far inferior using near-identical chemotherapy strategies. Recently, there has been a plethora of newer agents designed to target distinguishing cellular and molecular features of specific PTCL subtypes.
These agents have been proven to yield superior anti-lymphoma responses and, in some cases, overall survival in the relapsed, refractory, and frontline treatment setting. In this review, we will summarize and highlight the most influential clinical trials leading to the Food and Drug Administration (FDA) approval of several novel therapeutic agents against PTCL, with an emphasis on emerging studies and strategies to expand their potential use in the frontline treatment setting.
论文信息
- 作者
- Angelos MG、Ballard HJ、Barta SK
- 单位
- Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.United States
- 文献类型
- 综述
- 期刊
- Journal of personalized medicine2022 Feb 11
- 原文标识
- PubMed 35207754 · DOI 10.3390/jpm12020267
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →